

# ***Current Chemical Research***

## **GUIDELINES FOR AUTHORS**

### **SCOPE OF JOURNAL**

The *Current Chemical Research* is devoted to the rapid publication of fundamental research papers on all phases of chemical research.

### **PLAGIARISM**

We resolutely condemn plagiarism, unauthorized use of published literature, fabricating research results, and all other malicious and intentional conduct. If we discover any misconduct, we will reject the submission immediately.

### **TYPES OF MANUSCRIPTS**

Manuscripts submitted to the *Current Chemical Research* should be **Review** or **Full Paper**.

**1. Review :** Review introduces the reader to a particular area of an author's research through a concise overview of a selected topic.

**2. Full Paper :** Full Paper must either be of a current general interest or of great significance to a more specialized readership. It is peer reviewed and report details of studies that have not been published previously, except in the form of primary communications.

A modular version of these guidelines is available as separate PDF file on the internet at <http://www.mehtapress.com>

### **MANUSCRIPT SUBMISSION**

The *Current Chemical Research* accepts manuscripts only via M X Press (Secure Online Manuscript Submission System). Author must be able to provide manuscript as complete word-processor and PDF files including text, tables, graphics for online submission.

Author must fulfill formatting requirements mentioned in 'MANUSCRIPT PREPARATION' during submission

**A. Manuscript** : The author should submit complete manuscript including text, tables, graphics in both wordprocessor and PDF files.

**B. Cover Letter** : A cover letter must be

uploaded with every manuscript in PDF format at the same as manuscript uploaded. The cover letter should contain,

- a. The corresponding author's name, postal and e-mail addresses, telephone and fax numbers.
- b. The title of the manuscript and a brief paragraph explaining significance of the work.

### **AUTHOR'S RESPONSIBILITY**

The authors should provide a statement attesting to the originality of the study they have submitted for consideration.

Authors have a responsibility to be forthright when complying with journal submission requirements. This entails disclosure about the originality of the content, a statement of an author's actual contribution to the study, and financial and conflict of interest disclosures.

### **DISCLAIMER**

Every effort is made by the Publisher to see that no inaccurate or misleading data, opinion or statement appear in journal. However, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor, sponsor or advertiser concerned. Accordingly, Publisher accepts no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

### **PUBLICATION ETHICS**

All the listed authors have to agree on all contents and they are responsible for all informations included in the text.

The corresponding author is responsible for all communications between the Journal and all coauthors, before and after publication.

The corresponding author has to make a statement confirming that the content of the manuscript represents the views of the coauthors, that neither the corresponding author nor the coauthors have submitted duplicate or overlapping manuscripts elsewhere, and that the

items indicated as personal communications in the text are supported by the referenced person.

Any changes to the author list after submission, such as a change in the order of the authors, or the deletion or addition of authors, need to be approved by every author.

The authors warrant that the manuscript is original and contains no matter which is defamatory or is otherwise unlawful or which invades individual privacy or infringes any proprietary right or any statutory copyright.

## PERMISSIONS FOR REPRODUCING

Authors should include with their submission, copies of written permission to reproduce material published elsewhere (such as illustrations) from the copyright holder. Authors are responsible for paying any fees to reproduce material.

## CONFLICT OF INTEREST

Public trust in the peer review process and the credibility of published articles depend in part on how well conflict of interest is handled during writing, peer review, and editorial decision making. Conflict of interest exists when an author (or the author's institution), reviewer, or editor has financial or personal relationships that inappropriately influence his or her actions. These relationships vary from those with negligible potential to those with great potential to influence judgment, and not all relationships represent true conflict of interest. The potential for conflict of interest can exist whether or not an individual believes that the relationship affects his or her scientific judgment. Financial relationships are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, and of science itself.

## PEER REVIEW

*Current Chemical Research* is a peer-review journal, so all papers are evaluated by this system. If the paper follows the scope of the journal, it will be sent to two or three independent reviewers, selected by the editors.

### Timing

The review process will ordinarily require two weeks.

## PEER REVIEW POLICY

All submitted manuscripts are read by the editorial staff. To save time for authors and peer-reviewers, only those papers that seem most likely to meet our editorial criteria are sent for formal review. Those papers judged by the editors to be of insufficient general interest or otherwise inappropriate are rejected promptly without external .

Manuscripts judged to be of potential interest to our readership are sent for formal review, typically to two or three reviewers. The editors then make a decision based on the reviewers' advice, from among several possibilities:

- Accept, with minor corrections;
- Invite the authors to revise their manuscript to address specific concerns before a final decision is reached;
- Reject, but indicate to the authors that further work might justify a resubmission;
- Reject outright, typically on grounds of specialist interest, lack of novelty, insufficient conceptual advance or major technical and/or interpretational problems.

## MANUSCRIPT PREPARATION

**Title:** The title should be accurately, clearly and grammatically correct and concisely reflect emphasis and content of the manuscript.

**Authors and Addresses:** Authors' names include all those who have made substantial contributions to the works even in the manuscript was actually written by only one person use first name, middle name and surnames. At least one author must be designated with an asterisk (\*) as the author to whom correspondences should be addressed. The names and addresses of the institution(s) where the work was performed should be listed in the following paragraph. If this is different from the present address, this should be noted in footnote.

**Corresponding Author's E-mail Address:** The email address of the corresponding author should be placed on a separate line below the institution addresses.

**Abstract:** The abstract allows the reader to identify the nature and scope of the manuscript and helps the editors recognize key features for indexing and retrieval.

**Keywords:** 5-6 keywords should be provided directly below the abstract.

**Introduction:** The introduction should be placed the work in the appropriate context and clearly state the purpose and objectives of the research.

**Experimental:** It is necessary to note types of instruments used for obtaining physicochemical characteristics of compounds; either the sources of the nontrivial reagents used should be specified or references for their synthesis should be given.

The title of each experiment should include the chemical name of the compound and the assigned compound number in Arabic bold face, however once one is chosen is must be used throughout the manuscript. Each previously unreported compound must be supported by adequate spectral data and elemental analyses.

All elemental analytical data will be published. In molecular formulas, elements should be arranged according to the Chemical Abstracts System.

Physical constants and spectral characteristics should be tabulated.

**Crystallographic Data:** Data and graphics vital to the discussion and should be included in the 'Result and Discussion'. If the data are used solely for confirming compound identify or stereochemistry, a statement in the 'Results and Discussion' or 'Experimental' that the assignment in supported by an X-ray crystallographic structure determination is usually sufficient.

**Powder Diffraction Data:** The authors are encouraged to present X-ray powder diffraction data for new or previously uncharacterized materials. In cases of unindexed listing of the data, the d spacings of all observed lines should be listed in sequence, together with their relative intensities. When filtered radiation is used, every effort should be made to identify residual  $\beta$  lines. Where resolution into  $\alpha_1$ - $\alpha_2$  doublets occurs, the identification of the d spacing for each line as  $d\alpha_1$ ,  $d\alpha_2$  gives a measure of the quality of the diffraction pattern. Relevant information about the specimen used should be included.

**Structural Data:** Atomic coordinates for structures of macromolecules determine by X-ray,

NMR, or other methods should be deposited with Protein Data Bank (PDB). It is the author.s responsibility to obtain a file name for the macromolecule ; the file name must be referenced in the manuscript. Crystal structures of nucleic acids should be deposited with the Nucleic Acid Database (NDB).

**Biological Data:** Biological test methods must be referenced or described in sufficient detail to permit the experiments to be repeated by others. Standard compounds and established drugs should be tested on the same system for comparision, stastical limits for the biological data are usually required. Doses and concentrations should be expressed in molar quantities when comparisions of potencies are made with compounds having substantial differences in molecular weights. For inactive agents, the highest concentration or dose level tested should be indicated. For optically active substances, the optical purity should be clearly documanted, especially for the less active or inactive enantiomers or diastromers.

**Protein Sequence Data:** These data should be deposited with Protein Identification Resource National Biomedical Research Foundation, Georgetown University Medical Center, Washington,D.C. 20007. Authors of accepted manuscripts containing nucleotide sequences should submit the sequence data, preferably in computerreadable form plus information for annotation of the data and a copy of the paper to GenBank Submissions, National Center for Biotechnology Information (NCBI), Building 38A, Room 8N-805, 8600 Rockville Pike, Bethesda, Maryland 20894. A foot note should appear on the title page indicating that such a deposit has been made.

**Abbreviations:** Standard physicochemical methods and related terms as well as common reagents are designated by generally accepted English abbreviations. All nontrivial terms and abbreviations must be explained when mentioned for the first time. The following common abbreviations should be used:

$\mu$ g-microgram; mg-milligram; g-gram; nm-nanometer; mm-millimeter; cm-centimeter; ml-milliliter; °C-degree centigrade; K-kelvin scale; J-joule; kJ-kilo joule; A-ampere; mA-milliampere; V-Volt; mV-millivolt; Hz-hertz;

MHz-megahertz; W-watt; mol-mole; mmol - millimole; mol/l-molar concentration; 1N-one normal (solution); M-molecular mass; eq.-equivalent; m.p.-melting point; b.p.-boiling point; h-hour; min-minute; s-second.

Abbreviations of words secondary and tertiary should be written before names as sec- and tert- while before formulas as s- and t-. Abbreviations of prefixes ortho-, meta-para- etc. should be written as o-, m-, p-. For solvents following abbreviations may be used

AcOH-acetic acid; Ac<sub>2</sub>O-acetic anhydride; AcOEt/ EtOAc -ethyl acetate; BuOH-butyl alcohol; s-BuOHsec-butyl alcohol; t-BuOH -tert-butyl alcohol; DMF -N,N-dimethyl formamide; DMSO-dimethyl sulfoxide; EtOH - ethyl alcohol; Et<sub>2</sub>O- diethyl ether; MeOH - methyl alcohol; Me<sub>2</sub>CO - acetone; MeCN-acetonitrile; PhOH - phenol; PhCl - chlorobenzene; PhMe - toluene; i-PrOH - isopropyl alcohol; THF - tetrahydrofuran etc.

For reagents, radicals, ligands, protecting groups: Ac - acetyl; Acac-acetyl acetone; Ad-adamantyl; Alk - alkyl; All-allyl; Ar-aryl; Bn-benzyl (PhCH<sub>2</sub>); Bu- butyl (s-Bu,i-Bu,t-Bu respectively); Bz-benzoyl (PhCO); Cbm-carbamoyl; Cp-cyclopentadienyl; en-ethylenediamine (as ligand only); Et-ethyl; Hal- halogen; Het - hetryl; Memethyl; Mes-Mesityl; Ph- phenyl; Pr- propyl; i-Pr- isopropyl; Py-pyridine; Pf-trifluoromethanesulfonyl; Ts- tosyl; Vin-vinyl as well as common designations for amino acids, carbohydrates and protecting groups.

Author should emphasize any unexpected or new hazards encountered and appropriate precautions in experimental reported work.

**Nomenclature:** Authors should use a systematic name similar to those used by Chemical Abstract Service and IUPAC for each compound whose preparation is reported in the .Experimental. or in the .Supplementary Information . IUPAC guide to macromolecular nomenclature are available at <http://www.iupac.org/publications/books/author/metanomski.html> and <http://www.iupac.org/reports/iv/guide.html>. For certain specialized classes of compounds such as steroids, peptides, carbohydrates, and cyclophanes, the names should conform to the nomenclature conventions generally accepted for that class.

Complex compounds with unduly lengthy

or unwieldy names should be referred to by their functional class and structure number in the text.

**Tables:** The use of tables is encouraged to present data in a space-efficient manner. Tables must be inserted in the manuscript word-processor file near their first mention in the text. They should be created with the word processor's table-formatting feature. Each data entry should be placed within its own table cell; tabs and line returns should not be used within cells. Arrangements that leave many columns only partially filled should be avoided.

Footnotes within tables should be given lowercase italic letter designations and should be cited in the table with lowercase italic superscripted letters. The sequence of letters should proceed by row, and from left to right within any rows having more than one footnote. If a reference is cited both in the text and in a table, the lettered footnote in the table should cite the text reference's number.

Above each table should be typed in bold-face characters, a sequential Arabic table number and short descriptive title. Whether possible, structure number should be used in table rather than small structural graphics. A table that contains one or more structures or other graphics is considered a single graphic for journal production. The table number title and any footnotes should not be included in the graphic but should be typed in the manuscript text file.

**Graphics:** All graphics (illustrations) must be prepared in digital format and inserted into the manuscript word processor file near their first mention in the text. Graphics intended to appear in black and white or grayscale should not be submitted in colour. When areas in a graphic created with a graphics program need to be shaded or filled in parallel lines or crosshatching, rather than gray shading, should be used whenever possible to allow the graphic to be processed as line art rather than as grayscale art.

The editors encourage the use of colour in manuscript graphics when it is important for clarity of presentation.

The quality of the graphics published in the journal depends on the quality of the graphic images provided by authors. Digital graphics should have minimum resolution.

Black and white line art 1200dpi

Grayscale art 600dpi

Colour art 300dpi

For uniformity of appearance, all the graphics of the same type should share a common graphic style and font. Structures, schemes and other drawings are made with standard drawing programme - most preferable advanced version of ChemDraw. For scanned halftone figures a resolution of 300 dpi insufficient. Scanned figures compressed with JPEG usually give no problems.

**Results & Discussion:** The presentation of experimental detail in the Results & Discussion section should be kept to minimum. Reiteration of information that is made obvious in tables, figures, or reaction schemes should be avoided.

**Conclusions:** If an optional conclusion section is used, its content should not substantially duplicate the abstract.

**Acknowledgement:** This section may be used to acknowledge helpful discussion with colleagues, technical assistance, gifts of starting material or reference samples, data from individual providers of spectroscopic, analytical or crystallographic services who are not coauthors, and financial support.

**References and Footnotes:** Authors should be judicious in citing the literature; unnecessarily long list of references should be avoided. Any articles, communications, letters, patents, theses, and conference abstracts in which portions of the reported work have been previously disclosed must be cited long footnotes should be avoided; additional data and peripheral discussion should be placed in the Supplementary Information rather than in footnotes.

All the references and footnotes must be placed together in a list at the end of the manuscript text. They should be numbered with Arabic numerals in the order of the first citation in the text, and the corresponding numbers inserted at the appropriate locations in the text as superscripted numerals with square brackets. It is crucial that authors verify their accuracy. Authors should consult a recent issue of the journal or ask editorial help.

## **Journal**

Author, Journal Abbreviation; **Volume(Issue)**, Page **(Year)**.

## **Book**

Author, Book Title, Edition Number, Editor, Publisher, Place of Publication, **Volume**, Page **(Year)**.

## **Meeting and Conference**

Author, Name of Meeting or Proceeding, Location of Meeting, Date of Meeting, Abstract Number, Page **(Year)**.

## **Patent**

Patent Owner, Title of Patent, Patent Number, **(Year)**.

## **Thesis**

Author, Level of Thesis, Degree-Granting University, Location of University, **(Year)**.

## **Computer Program**

Author, Program Title (Version or Edition), Publisher, Place of Publication, **(Year)**.

## **Website**

In parentheses, show the date, the site was last accessed the date you checked to make sure the site was still online and the URL, separated by a semicolon. Do not use ending punctuation.

## **PROOFS**

Proofs will be sent electronically. Only typographic corrections and other minor changes may be made in a galley proof. Any substantive changes will require editorial approval and may delay publication.

## **REPRINTS**

E-reprint can be accessed free of cost by corresponding author.

Printed reprints can be ordered during galley proof stage.

## **CHARGES**

Corresponding author will be charged 1000 INR/ 38 USD towards DOI assignment, plagiarism checking and labour charges of manuscript layout preparation after publication of manuscript.

## **SINGLE ISSUE COST**

Cost of single published issue (Hardcopy) is 1500 INR/55 USD.